🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsReta hype is insane but I am cautiously optimistic

Reta hype is insane but I am cautiously optimistic

SkepticalSean Mon, Apr 13, 2026 at 2:57 AM 11 replies 731 viewsPage 1 of 3
SkepticalSean
Member
98
345
Jan 2025
Maine
Apr 13, 2026 at 2:57 AM#1

Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does not support as firmly as people think.

What would genuinely help is knowing what the phase 2 dropout pattern implies about how the phase 3 tolerability will read.

Happy to be told the question itself is wrong.

29 24DerekSJ_a1c, paige_pharma, emma_london and 26 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Apr 13, 2026 at 3:39 AM#2

Answering the narrow version, because the broad one does not have a single answer. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

28 23NauseaFreeNow, SteveThurs, B12Beth and 25 others
Reply Quote Save Share Report
MikeFit_NJ
Senior Member
1,567
6,543
Apr 2024
New Jersey
Apr 13, 2026 at 4:21 AM#3
Dr.NateNeph said:
It helps to say which part of this you are uncertain about.

Dr.NateNeph has the substance of this right. The condition it depends on is worth stating. The glucagon component looks paradoxical and is not. Glucagon receptor agonism raises energy expenditure and drives hepatic fatty-acid oxidation, and its hyperglycaemic tendency is offset by the GLP-1 arm's insulin secretagogue effect. Net result: intake down from GLP-1/GIP, expenditure up from glucagon, glycaemia neutral or improved. It is a balancing act, and it is why the liver-fat results are the most interesting part of the dataset.

27 22DeniseRN_TPA, SandraNC_45, Dr.EndoIndy and 24 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
Apr 13, 2026 at 5:03 AM#4
SkepticalSean said:
Reading the retatrutide phase 2 data properly rather than the headline, and the 24% figure is doing a lot of work that the confidence interval does…

This matches mine closely enough to be worth saying so out loud. The detail I would add is minor and it is already implied above.

26 21SarahChen_PharmD, sarah.morrison, NeuroNate and 23 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Apr 13, 2026 at 9:00 AM#5

From the other side of the consultation, briefly. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

25 20mike_nyc, VendorMark, COA_Karl and 22 others
Reply Quote Save Share Report

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register